Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. uri icon

authors

  • Lowe, S L
  • Ardayfio, P
  • Aguiar, G
  • Ishibai, M
  • Takaichi, G
  • Chua, L
  • Mullins, G
  • Sims, J R
  • Duggan Evans, C
  • Shcherbinin, S
  • Cheng, Y-J
  • Willis, B A
  • Gueorguieva, I
  • Lo, A C
  • Fleisher, A S
  • Dage, J L

publication date

  • 2021